Recursion Pharmaceuticals Inc
Geschlossen
BrancheGesundheitswesen
3.16 0.96
Übersicht
Veränderung der Aktienkurses
24h
Min
3.14
Max
3.18
Einkommen | -9.4M -118M |
|---|---|
Verkäufe | -29M 6.5M |
EPS | -0.22 |
Gewinnspanne | -1,815.575 |
Angestellte | 600 |
EBITDA | -20M -109M |
Empfehlungen | Buy |
|---|---|
12-Monats-Prognose | +134.29% upside |
Nächstes Ergebnis | 4. Aug. 2026 |
|---|
Marktkapitalisierung | -109M 1.8B |
|---|---|
Vorheriger Eröffnungskurs | 2.2 |
Vorheriger Schlusskurs | 3.16 |
Nachrichtenstimmung
By Acuity
50%
50%
146 / 342 Ranking in Healthcare
Recursion Pharmaceuticals Inc Chart
Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.
Über Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.